Rekah Pharmaceutical Industry Ltd.

TASE:REKA Rapporto sulle azioni

Cap. di mercato: ₪162.3m

Rekah Pharmaceutical Industry Gestione

Gestione criteri di controllo 4/4

Rekah Pharmaceutical Industry Il CEO è Mordechai Elgrabli, nominato in Apr2015, e ha un mandato di 9.58 anni. la retribuzione annua totale è ₪ 1.01M, composta da 100% di stipendio e 0% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 15.32% delle azioni della società, per un valore di ₪ 24.86M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.5 anni e 9.6 anni.

Informazioni chiave

Mordechai Elgrabli

Amministratore delegato

₪1.0m

Compenso totale

Percentuale dello stipendio del CEO100.0%
Mandato del CEO9.6yrs
Proprietà del CEO15.3%
Durata media del management8.5yrs
Durata media del Consiglio di amministrazione9.6yrs

Aggiornamenti recenti sulla gestione

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Recent updates

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Jul 11
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Jul 05
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Sep 12
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Jul 19
Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

Apr 13
Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

May 12
We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Apr 09
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Mar 12
Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 19
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Jan 29
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

Jan 08
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Dec 18
How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Nov 30
Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mordechai Elgrabli rispetto agli utili di Rekah Pharmaceutical Industry?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

₪7m

Mar 31 2024n/an/a

-₪6m

Dec 31 2023₪1m₪1m

-₪7m

Sep 30 2023n/an/a

-₪8m

Jun 30 2023n/an/a

-₪3m

Mar 31 2023n/an/a

-₪2m

Dec 31 2022₪845k₪845k

-₪2m

Sep 30 2022n/an/a

₪4m

Jun 30 2022n/an/a

₪3m

Mar 31 2022n/an/a

₪5m

Dec 31 2021₪830k₪830k

₪7m

Sep 30 2021n/an/a

₪5m

Jun 30 2021n/an/a

₪9m

Mar 31 2021n/an/a

₪10m

Dec 31 2020₪828k₪828k

₪11m

Sep 30 2020n/an/a

₪7m

Jun 30 2020n/an/a

₪5m

Mar 31 2020n/an/a

₪4m

Dec 31 2019₪832k₪832k

₪3m

Sep 30 2019n/an/a

₪6m

Jun 30 2019n/an/a

₪5m

Mar 31 2019n/an/a

₪7m

Dec 31 2018₪801k₪801k

₪8m

Sep 30 2018n/an/a

₪246k

Jun 30 2018n/an/a

-₪8m

Mar 31 2018n/an/a

-₪11m

Dec 31 2017₪795k₪795k

-₪21m

Compensazione vs Mercato: La retribuzione totale di Mordechai ($USD 273.32K ) è inferiore alla media delle aziende di dimensioni simili nel mercato IL ($USD 420.33K ).

Compensazione vs guadagni: La retribuzione di Mordechai è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Mordechai Elgrabli (80 yo)

9.6yrs

Mandato

₪1,013,000

Compensazione

Mr. Mordechai Elgrabli has been the Chief Executive Officer of Rekah Pharmaceutical Industry Ltd since August 24, 1993 and its Director since August 24, 1993. Mr. Elgrabli is a Member of Presidium of Mofet...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Mordechai Elgrabli
CEO & Director9.6yrs₪1.01m15.32%
₪ 24.9m
Georgette Elgrabli
Director of Industrial Division & Directorno data₪1.62m15.32%
₪ 24.9m
Jacob Elgrably
Chief Executive Officer of Ophir Shalpharm7.5yrs₪920.00kNessun dato
Nir Sella
Chief Executive Officer - Fresh of Life Pharma Ltd.3.1yrs₪907.00kNessun dato
Meir Melumad
Director of Operationsno data₪684.00kNessun dato
Yuval Elgrabli
Deputy CEO & Director of Business Development13.7yrsNessun datoNessun dato
Yaakov Elgrabli
Chief Executive Officer of Ophir & Shalpharm Ltdno data₪705.00k0.026%
₪ 42.7k

8.5yrs

Durata media

67.5yo

Età media

Gestione esperta: Il team dirigenziale di REKA è esperto e expertise (durata media dell'incarico 8.5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Mordechai Elgrabli
CEO & Director31.3yrs₪1.01m15.32%
₪ 24.9m
Georgette Elgrabli
Director of Industrial Division & Director31.3yrs₪1.62m15.32%
₪ 24.9m
Ishay Davidi
Director9.6yrsNessun datoNessun dato
Avraham Bigger
Chairman9.6yrs₪400.00kNessun dato
Orly Zilberman
Independent External Director9.6yrsNessun datoNessun dato
Arnon Zo-Haaretz
Independent External Director8yrsNessun datoNessun dato
Ehud Nissan
Independent External Director8yrsNessun datoNessun dato
Amir Widmann
Directorless than a yearNessun datoNessun dato

9.6yrs

Durata media

67.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di REKA sono considerati esperti (durata media dell'incarico 9.6 anni).